MicroRNAs: a novel therapeutic target for schizophrenia.

Hdl Handle:
http://hdl.handle.net/10147/201254
Title:
MicroRNAs: a novel therapeutic target for schizophrenia.
Authors:
Bravo, Javier A; Dinan, Timothy G
Affiliation:
Department of Psychiatry, Cork University Hospital, Wilton, Cork, Ireland.
Citation:
MicroRNAs: a novel therapeutic target for schizophrenia. 2011, 17 (2):176-88 Curr. Pharm. Des.
Journal:
Current pharmaceutical design
Issue Date:
2011
URI:
http://hdl.handle.net/10147/201254
PubMed ID:
21355836
Abstract:
Schizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21-23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.
Item Type:
Article
Language:
en
Description:
Schizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21-23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.
MeSH:
Animals; Antipsychotic Agents; Central Nervous System; Clinical Trials as Topic; Gene Expression Regulation; Humans; Mental Disorders; Mice; MicroRNAs; Molecular Targeted Therapy; Rats; Schizophrenia
ISSN:
1873-4286

Full metadata record

DC FieldValue Language
dc.contributor.authorBravo, Javier Aen
dc.contributor.authorDinan, Timothy Gen
dc.date.accessioned2012-01-10T13:58:45Z-
dc.date.available2012-01-10T13:58:45Z-
dc.date.issued2011-
dc.identifier.citationMicroRNAs: a novel therapeutic target for schizophrenia. 2011, 17 (2):176-88 Curr. Pharm. Des.en
dc.identifier.issn1873-4286-
dc.identifier.pmid21355836-
dc.identifier.urihttp://hdl.handle.net/10147/201254-
dc.descriptionSchizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21-23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.en
dc.description.abstractSchizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21-23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.-
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAntipsychotic Agents-
dc.subject.meshCentral Nervous System-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshGene Expression Regulation-
dc.subject.meshHumans-
dc.subject.meshMental Disorders-
dc.subject.meshMice-
dc.subject.meshMicroRNAs-
dc.subject.meshMolecular Targeted Therapy-
dc.subject.meshRats-
dc.subject.meshSchizophrenia-
dc.titleMicroRNAs: a novel therapeutic target for schizophrenia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Psychiatry, Cork University Hospital, Wilton, Cork, Ireland.en
dc.identifier.journalCurrent pharmaceutical designen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.